INmune Bio, Inc. (NASDAQ:INMB) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET

Company Participants

David Moss – Co-Founder and Chief Financial Officer

RJ Tesi – Chairman and Chief Executive Officer

CJ Barnum – Head of Neuroscience

Conference Call Participants

William Wood – B. Riley Securities

Matthew Cross – Alliance Global Partners

Sung Hong – BTIG

Daniel Carlson – TW Research Group

Operator

Greetings, and welcome to the INmune Bio First Quarter 2022 Earnings Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded. A transcript will follow within 24 hours of this conference call.

At this time, it is my pleasure to introduce Mr. David Moss, Co-Founder and CFO of INmune Bio. David, the floor is yours.

David Moss

Thank you, Paul, and good afternoon, everybody. We thank you for joining us for the call for INmune Bio's first quarter 2022 financial results. With me on the call is Dr. RJ Tesi, CEO and Co-Founder of INmune Bio, who will provide a business update on our DN-TNF platform; and Dr. CJ Barnum, Head of Neuroscience, who will speak about both of our Phase 2 programs in Alzheimer's disease and our Phase 2 program in treatment-resistant depression.

Before we begin, I remind everyone that except for statements of historical facts, the statements made by management and responses to questions on this conference call are forward-looking statements under the safe harbor provision of the Private Securities Litigation Act Reform of 1995. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Please see the forward-looking statements disclaimer on the company's earnings press release, as well as risk factors in the company's SEC filings, including our most recent quarterly filing with the SEC.

There's no assurance of any specific outcome. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made as of the facts and circumstances underlying these forward-looking statements may change. Except as required by law, INmune Bio disclaims any obligations to update these forward-looking statements to reflect future information events or circumstances.

Now, to start, I'd like to state that we are very optimistic about the developments on our two platforms, INKmune from NK cells and XPro for CNS indications. Both platforms have significant potential and we like to say that what we're pursuing today is just the tip of the iceberg. To update you on our progress, I'd like to turn the call over to Dr. RJ Tesi, Co-Founder and CEO of INmune Bio. RJ?